Allergic Contact Dermatitis
25
2
3
15
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 25 trials
100.0%
+13.5% vs benchmark
12%
3 trials in Phase 3/4
40%
6 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (25)
The Effects of Dupilumab on Allergic Contact Dermatitis
Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Rate of Allergic Contact Dermatitis and Cosmetic Outcomes
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
Patient Experience and Quality of Patch Testing on the Legs vs Back
Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
Bioequivalence of Ethylenediamine Dihydrochloride Study
Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool
Allergy Skin Patch Artificial Intelligence (AI)
Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
Immune Reactions in Contact Dermatitis Affected Skin
Epidemiology and Co-Reactivity of Novel Surfactant Allergens
Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis
Nickel Desensitization Using Topical Therapy